Yudkin JS, Juhan-Vague I, Hawe E, Humphries SE, di Minno G, Margaglione M, Tremoli E, Kooistra T, Morange PE, Lundman P, Mohamed-Ali V, Hamsten A, Hifmech Study Group. HIFMECH Study Group. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism. 2004 Jul;53(7):852-7.
Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. Curr Med Res Opin. 2004 Jan 1;20(12):1883-93. doi: 10.1185/030079904X11510.
Shadoan MK, Anthony MS, Rankin SE, Clarkson TB, Wagner JD. Effects of tibolone and conjugated equine estrogens with or without medroxyprogesterone acetate on body composition and fasting carbohydrate measures in surgically postmenopausal monkeys. Metabolism. 2003 Sep;52(9):1085-91.
Mikkola TS, Anthony MS, Clarkson TB, St. Clair RW. Serum cholesterol efflux potential in postmenopausal monkeys treated with tibolone or conjugated estrogens. Metabolism. 2002 Apr;51(4):523-30.
Watson ME, Lacey LA, McSorley DJ, Kong NS, Northcutt AR, Mangel AW. Patient satisfaction with alosetron for the treatment of irritable bowel syndrome (IBS). Poster presented at the Digestive Disease Week and the 101st Annual Meeting of the American Gastroenterological Association; May 2000. [abstract] Gastroenterology. 2000 Apr; 118((4) Part 1):A219.
Northcutt AR, Camilleri M, Mayer EA, Dossman DA, Dukes GE, Ehsanullah RSB, McSorley DJ. Alosetron, a 5-HT3-receptor antagonist, is effective in the treatment of female irritable bowel syndrome patients. Gastroenterology. 1998;114:A812.
Wagner JD, Cefalu WT, Anthony MS, Litwak KN, Zhang L, Clarkson TB. Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys. Metabolism. 1997 Jun;46(6):698-705.
Vakil N, McSorley DJ. The incremental cost and utility of cultures for helicobacter pylori. Gastroenterology. 1997;112(4):A319.
Perschy TB, McSorley DJ. Ranitidine bismuth citrate in combination with clarithromycin is effective against h. pylori strains with susceptible or intermediate clarithromycin sensitivity. Gastroenterology. 1997;112(4):A257.
Wagner JD, Martino MA, Jayo MJ, Anthony MS, Clarkson TB, Cefalu WT. The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. Metabolism. 1996 Oct;45(10):1254-62.
Peterson WL, Sontag SJ, Ciociola AA, Sykes DL, McSorley DJ, Webb DD, the H. pylori Ulcer Group. Ranitidine bismuth citrate plus clarithromycin is effective in the eradication of helicobacter pylori and prevention of duodenal ulcer relapse. Poster presented at the Digestive Disease Week and the 95th Annual Meeting of the American Gastroenterological Association; May 1995. [abstract] Gastroenterology. 1995 Apr; 108(4 (Suppl 1)):A190. doi: 10.1016/0016-5085(95)23422-5
Ciociola AA, Koch KM, McSorley DJ. Safety and pharmacokinetics of chronic oral dosing of gr122311x (ranitidine bismuth citrate), a new bismuth compound with anti-secretory activity. Gastroenterology. 1992;102(4):A50.
Ciociola AA, Koch KM, McSorley DJ. Safety and pharmacokinetics of ascending oral doses of gr122311x (ranitidine bismuth citrate), a new bismuth compound with anti-secretory properties. Gastroenterology. 1992;102(4):A51.